tradingkey.logo

Evolus Inc

EOLS
4.500USD
+0.090+2.04%
종가 02/06, 16:00ET시세는 15분 지연됩니다
291.45M시가총액
손실P/E TTM

Evolus Inc

4.500
+0.090+2.04%

자세한 내용은 Evolus Inc 회사

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.

Evolus Inc 정보

종목 코드 EOLS
회사 이름Evolus Inc
상장일Feb 08, 2018
CEOMoatazedi (David)
직원 수332
유형Ordinary Share
회계 연도 종료Feb 08
주소520 Newport Center Dr Ste 1200
도시NEWPORT BEACH
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호92660-7022
전화19492844555
웹사이트https://www.evolus.com/
종목 코드 EOLS
상장일Feb 08, 2018
CEOMoatazedi (David)

Evolus Inc의 회사 임원진

이름
이름/직위
직위
주식 보유
변동
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+23000.00%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
+104603.00%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+30000.00%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-5900.00%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-127905.00%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+23000.00%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
+104603.00%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+30000.00%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-5900.00%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-127905.00%

수익 분석

기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.

주식 보유 통계

마지막 업데이트: Sun, Nov 16
마지막 업데이트: Sun, Nov 16
주주
주주 유형
주주
주주
비율
Nantahala Capital Management, LLC
8.84%
Tang Capital Management, LLC
8.47%
Lynch (Timothy Patrick)
7.92%
Caligan Partners, LP
6.39%
BlackRock Institutional Trust Company, N.A.
6.15%
기타
62.24%
주주
주주
비율
Nantahala Capital Management, LLC
8.84%
Tang Capital Management, LLC
8.47%
Lynch (Timothy Patrick)
7.92%
Caligan Partners, LP
6.39%
BlackRock Institutional Trust Company, N.A.
6.15%
기타
62.24%
주주 유형
주주
비율
Hedge Fund
39.18%
Investment Advisor
21.75%
Investment Advisor/Hedge Fund
15.75%
Individual Investor
10.05%
Private Equity
4.06%
Corporation
3.30%
Research Firm
2.38%
Pension Fund
0.43%
Bank and Trust
0.25%
기타
2.85%

기관 주식 보유

마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
356
58.38M
89.22%
--
2025Q3
366
58.59M
90.20%
-409.50K
2025Q2
368
58.97M
91.09%
+3.93M
2025Q1
354
55.05M
88.70%
-1.35M
2024Q4
343
52.59M
87.55%
+1.63M
2024Q3
334
50.95M
89.20%
-1.08M
2024Q2
328
52.17M
86.99%
+2.08M
2024Q1
314
50.10M
82.52%
-553.42K
2023Q4
296
45.99M
83.45%
+2.48M
2023Q3
294
41.91M
82.26%
+3.40M
더 보기

주주 활동

이름
보유 주식
비율
변동
Chg %
날짜
Nantahala Capital Management, LLC
5.73M
8.84%
+1.53M
+36.42%
Sep 30, 2025
Tang Capital Management, LLC
5.49M
8.47%
+490.90K
+9.82%
Sep 30, 2025
Lynch (Timothy Patrick)
5.13M
7.92%
+1.04M
+25.38%
Sep 30, 2025
Caligan Partners, LP
4.14M
6.39%
+796.97K
+23.85%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.99M
6.15%
+339.54K
+9.30%
Sep 30, 2025
The Vanguard Group, Inc.
3.42M
5.27%
+110.69K
+3.35%
Sep 30, 2025
Frazier Life Sciences Management, L.P.
2.63M
4.06%
+195.12K
+8.01%
Sep 30, 2025
Medy Tox Inc
2.14M
3.3%
-1.24M
-36.82%
Dec 31, 2024
Millennium Management LLC
1.86M
2.87%
+375.58K
+25.32%
Sep 30, 2025
Stonepine Capital Management, LLC
1.54M
2.37%
+619.89K
+67.64%
Sep 30, 2025
더 보기

관련 ETF

마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
State Street SPDR S&P Pharmaceuticals ETF
0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.93%
iShares U.S. Pharmaceuticals ETF
0.15%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
더 보기
State Street SPDR S&P Pharmaceuticals ETF
비율0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
비율0.93%
iShares U.S. Pharmaceuticals ETF
비율0.15%
iShares Micro-Cap ETF
비율0.07%
ProShares Ultra Nasdaq Biotechnology
비율0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
비율0.06%
Invesco Nasdaq Biotechnology ETF
비율0.04%
ProShares Hedge Replication ETF
비율0.02%
iShares Russell 2000 Growth ETF
비율0.02%
Schwab U.S. Small-Cap ETF
비율0.01%

주식 배당금

지난 5년 동안 총 0.00 USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음

주식 분할

날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
KeyAI